Companies Economy Live May 24, 2025 0 Comments

Healthcare Global Enterprises’ Q4 PAT drops 65% despite 18% revenue growth

HCG’s consolidated income from operations rose 18% y-o-y to ₹5,85.1 crore, compared to ₹494.6 crore in the corresponding quarter last year

Bengaluru-based oncology-focused specialty healthcare provider Healthcare Global Enterprises (HCG) reported a sharp decline in profitability for the quarter ended March 31, 2025, even as revenue and operational performance saw healthy growth.

The company saw its consolidated profit after tax (PAT) decline by 65 per cent year-on-year (y-o-y) to ₹7.4 crore down from ₹21.3 crore in the corresponding quarter past year.

Consolidated income from operations rose 18 per cent y-o-y to ₹5,85.1 crore, compared to ₹494.6 crore in the corresponding quarter of the previous year. EBITDA grew 14 per cent to ₹107 crore with a margin of 18.3 per cent, slightly lower than the 19 per cent reported in the year-ago period.

Profit before tax also declined significantly by 52 per cent to ₹13.6 crore in Q4FY25 from ₹28.2 crore a year earlier, with PAT margins narrowing to 1.3 per cent from 4.3 per cent.

EBITDA for established centres grew 15 per cent y-o-y, reaching ₹115.4 crore, while EBITDA from emerging centres increased to ₹7 crore, up from ₹4.9 crore in Q4FY24.

“Over the past year, we have strengthened this position by upgrading our infrastructure across regions. Looking ahead, we are making focused investments in next-generation capabilities, especially in early cancer detection and precision medicine. In line with our commitment to cutting-edge diagnostics and research, we are pleased to share that we are acquiring the Orbitrap Astral Mass Spectrometer from Thermo Fisher Scientific—one of the most advanced platforms globally for high-resolution mass spectrometry,” said Dr BS Ajaikumar, Executive Chairman, HealthCare Global Enterprises Ltd.

“This acquisition will significantly enhance our molecular and proteomic profiling capabilities, enabling more precise disease characterisation and paving the way for next-generation biomarker discovery and targeted therapies,” he added.

Looking ahead, the company aims to accelerate digital initiatives, boost brand awareness, and expand access to its oncology services. A new 186-bed facility in Ahmedabad was inaugurated in April, with 118 operational beds to start with.